Operational EfficiencyThe company's operational initiatives, including a manufacturing and supply chain optimization program, are expected to yield significant cost savings, totaling around $560M by FY26.
Product Portfolio ExpansionThe launch of Opill, the first OTC oral contraceptive approved in the US, underscores Perrigo's dedication to expanding its product portfolio and commitment to growing consumer brands.
Strategic InitiativesPerrigo's transition from a generic Rx business to a pureplay consumer self-care business presents a significant opportunity for stock appreciation.